News and Events

Date Subject Download
2017-10-20

Medeon Biodesign Announces Successful Clinical Use of AbClose™ Laparoscopic Port Site Closure Device in the United States

TAIPEI, October 20, 2017 – Medeon Biodesign, Inc., a publicly traded medical device company headquartered in Taipei, is pleased to announce that its innovative laparoscopic port site closure device, AbClose™, successfully closed more than 50 wounds in a variety of laparoscopic surgeries. The device consistently demonstrated its simplicity, stability and predictability in the hands of multiple physicians in an ongoing pre-commercial clinical evaluation in the United States. 

The U.S. Food and Drug Administration 510(k) cleared AbClose™ is a revolutionary advancement in port site wound closure that enables fast, simple, and secure single-operator suturing and eliminates user variability. The purpose of the pre-commercial clinical evaluation is to assess physician preference for using the AbClose™ compared to other port site closure devices available on the market, in terms of ease of use, effective closure and time to complete closure. Data are collected from physicians across various specialties, including general surgery, bariatrics, obstetrics & gynecology, and urology. 

“Currently, there are 3.5 million laparoscopic procedures performed annually in the US across various procedure types, with 70% of the procedures requiring port site closure. AbClose™ is designed to reduce operating time, cost, and risk of port site hernia and minimize the frustrations experienced by surgical teams. This clinical evaluation has confirmed benefits of the product’s Grip180 technology, to ensure 180° suture placement on the incision, and addressed the pain point and frustration at the end of each surgery.” said Dr. Yue-Teh Jang, Chairman and CEO of Medeon Biodesign, Inc.

“Effective port site closure is challenging, especially in retroperitoneal laparoscopy. It is often very difficult to adequately visualize the trocar wound sites for effective closure as the retroperitoneal space is very small. The technical difficulty of such retroperitoneal trocar wound closure is further enhanced by the close proximity of several vital body structures and organs to the port sites. Even under these challenging situations, AbClose™ with its stabilization mechanism performed perfectly and consistently a with short learning curve.” stated Dr. Thomas Hsu, Clinical Professor of Urology at Stanford University School of Medicine, Palo Alto, California.
 
“Port site hernia happens in 1%-6% of all laparoscopic procedures, which may require additional hernia repair surgeries with significant cost to hospitals and patients. Prevention is the best approach to mitigate this risk, and therefore, there is a clinical need for an easy and reliable solution. AbClose™ automated 180-degree suture placement minimizes user variation and provides stable and predictable closure. It is a game changer. I am very pleased to have tried and experienced the excellent performance of AbClose™ and look forward to using it routinely in my practice.” said Dr. Dieter Bruno, President Elect and urologist at Sequoia Hospital, Redwood City, California.  

About Medeon Biodesign

Medeon Biodesign (TPEx: 6499) is a publicly traded company located in Taipei, Taiwan, and currently listed on Taipei Exchange. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. For more information, please visit www.medeonbio.com/en.

 

Contacts

Dr. Yi-Ju Chen

+886.2.2881.6686

ir@medeonbio.com

2017-05-02

Medeon Biodesign Announces Approval to Begin CE Clinical Study for the XProTM Large Bore Vascular Closure System

 

TAIPEI, May 2, 2017 – Medeon Biodesign, Inc., a Taiwan publically traded medical device company, is pleased to announce today that it has received approval by the Health and Disability Ethics Committees, Ministry of Health, New Zealand to commence the CE clinical trial for the XProTM Suture-Mediated Vascular Closure Device System (XProTM System), the company’s large bore closure device, at Auckland City Hospital in New Zealand.

The clinical study will assess the safety and effectiveness of the XProTM System to facilitate hemostasis in patients undergoing percutaneous endovascular procedures utilizing 8-18 Fr introducer sheaths via the common femoral artery, including Transcatheter Aortic Valve Implementation (TAVI), Endovascular Aneurysm Repair (EVAR), Thoracic Endovascular Aneurysm Repair (TEVAR), and Percutaneous Balloon Valvuloplasty (PBV) procedures. The prospective, multi-center, single arm study will enroll up to 60 patients in New Zealand and Australia. The results will support CE Mark regulatory submission.

XProTM System, the innovative suture-mediated closure device targeting percutaneous large bore procedures, had its safety and effectiveness demonstrated in first-in-man studies in late 2015 at Sanatorio Italiano Hospital in Asuncion, Paraguay. The device achieved immediate or rapid hemostasis at the puncture sites with excellent clinical outcomes, including fast ambulation and discharge from the hospital.

Dr. Mark Webster, an interventional cardiologist at Auckland City Hospital, who is also the principal investigator of this clinical study, stated “As TAVI procedures expand to intermediate and low risk patients, reducing all peri-procedural complications assumes greater importance. Access site complications from large bore vascular sheaths and valve delivery systems remain a concern, and are still a common cause of patient morbidity and, very occasionally, mortality. A dedicated, large bore vascular closure device with reproducible safety and efficacy has the potential to significantly lower the time, effort, and expense of these procedures, as well as improve patient outcomes.”

“I am very pleased to have witnessed the development of the XProTM system from its early conception to its present form. The system is easy to use and has certain distinct features and potential advantages over currently available pre-closure solutions.  Suture based pre-closure techniques allow physicians to optimize control over percutaneous large-bore access site hemostasis, and the XProTM System’s novel suture deployment mechanism has the potential to enhance safety, minimize risk of iatrogenic vessel narrowing and shorten procedure time.” notes Dr. Kendrick Shunk, an Interventional Cardiologist TAVI operator and Professor of Medicine at University of California, San Francisco, who also serves as a clinical advisor to Medeon Biodesign and Medical Monitor for this CE study.

“Optimal large bore vascular closure can be achieved by three simple steps with the XProTM System. Our suture mediated technology with built-in safety mechanisms is designed to assist interventionalists to manage procedures more efficiently while minimize potential complications associated with vessel narrowing and concerns arising from other technologies that leave behind foreign materials in the blood vessel.  The commencement of this clinical study will accumulate more clinical experience to demonstrate its safety, effectiveness, and reproducibility of this disruptive technology.” says Dr. Yue-Teh Jang, Chairman and CEO of Medeon Biodesign.

 

About Medeon Biodesign

Medeon Biodesign (TPEx: 6499) is a publicly traded company headquartered in Taipei, Taiwan, and currently listed on Taipei Exchange. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. For more information, please visit www.medeonbio.com/en.

 

Contacts

Dr. Yi-Ju Chen

+886.2.2881.6686

ir@medeonbio.com

2017-03-28

MEDEON BIODESIGN ANNOUNCES INVESTING IN PANTHER ORTHOPEDICS FOR ORTHOPEDIC EXTREMITY APPLICATIONS

TAIPEI, March 28, 2017 – Medeon Biodesign, Inc., a Taiwan medical device company, is pleased to announce that the Company led and successfully closed the Series A investment of Panther Orthopedics, Inc., a San Jose, CA start-up pioneering innovative dynamic fixation solutions for orthopedic extremity applications. 

The orthopedic extremity device market continues to expand rapidly, primarily due to procedure volume growth, lifestyle influences and favorable demographics. Nevertheless, the market need for better fixation products for both trauma and sports medicine in fracture fixation and joint stabilization applications is still under served. “Current options for fixation include cortical screw and suture button flexible fixation devices. However, many limitations associated with currently marketed products are not being addressed,” said Dr. Kathryn Stecco, CEO and co-founder of Panther Orthopedics. “We have developed an innovative platform for dynamic extremity fixation, which we believe will provide continuous compression during the healing period while still allowing micromotion. The intuitive design of our solutions is easy to use and intended to eliminate the need for most second surgery removal, providing significant benefits for both the patients and the entire healthcare system.”

"We are excited to lead the investment of Panther Orthopedics to address the long-standing need of better clinical fixation during the healing period for orthopedic extremity applications," said Dr. Yue-Teh Jang, CEO of Medeon Biodesign. “We are impressed with the team’s extensive experience, profound knowledge of orthopedic applications and broad KOL networking. We are confident that the Panther Orthopedics’ unique and innovative dynamic fixation solutions will be very welcome by the clinical community in the near future.”